References of "Gastroenterology"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailFactors determining therapeutic strategy at diagnosis and evolution of disease severity in a cohort of Belgian pediatric Crohn's disease patients (BELCRO)
De Greef, E; Mahachie John, Jestinah; Hoffman, I et al

in Gastroenterology (2012)

Detailed reference viewed: 12 (2 ULg)
Full Text
Peer Reviewed
See detailA feedback loop between the liver-enriched transcription factor network and mir-122 controls hepatocyte differentiation.
Laudadio, Ilaria; Manfroid, Isabelle ULg; Achouri, Younes et al

in Gastroenterology (2012), 142(1), 119-29

BACKGROUND & AIMS: Hepatocyte differentiation is controlled by liver-enriched transcription factors (LETFs). We investigated whether LETFs control microRNA expression during development and whether this ... [more ▼]

BACKGROUND & AIMS: Hepatocyte differentiation is controlled by liver-enriched transcription factors (LETFs). We investigated whether LETFs control microRNA expression during development and whether this control is required for hepatocyte differentiation. METHODS: Using in vivo DNA binding assays, we identified miR-122 as a direct target of the LETF hepatocyte nuclear factor (HNF) 6. The role and mechanisms of the HNF6-miR-122 gene cascade in hepatocyte differentiation were studied in vivo and in vitro by gain-of-function and loss-of-function experiments, using developing mice and zebrafish as model organisms. RESULTS: HNF6 and its paralog Onecut2 are strong transcriptional stimulators of miR-122 expression. Specific levels of miR-122 were required for proper progression of hepatocyte differentiation; miR-122 stimulated the expression of hepatocyte-specific genes and most LETFs, including HNF6. This indicates that HNF6 and miR-122 form a positive feedback loop. Stimulation of hepatocyte differentiation by miR-122 was lost in HNF6-null mice, revealing that a transcription factor can mediate microRNA function. All hepatocyte-specific genes whose expression was stimulated by miR-122 bound HNF6 in vivo, confirming their direct regulation by this factor. CONCLUSIONS: Hepatocyte differentiation is directed by a positive feedback loop that includes a transcription factor (HNF6) and a microRNA (miR-122) that are specifically expressed in liver. These findings could lead to methods to induce differentiation of hepatocytes in vitro and improve our understanding of liver cell dedifferentiation in pathologic conditions. [less ▲]

Detailed reference viewed: 91 (24 ULg)
Full Text
Peer Reviewed
See detailAdalimumab in ulcerative colitis: can pharmacodynamics be improved based on pharmacokinetics?
LOUIS, Edouard ULg; Panes, Julian

in Gastroenterology (2012), 142(1), 176-8

Detailed reference viewed: 12 (1 ULg)
Full Text
Peer Reviewed
See detailMaintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped.
Louis, Edouard ULg; Mary, J. Y.; Vernier-Massouille, G. et al

in Gastroenterology (2012), 142(1), 63-70531

BACKGROUND & AIMS: It is important to determine whether infliximab therapy can be safely interrupted in patients with Crohn's disease who have undergone a period of prolonged remission. We assessed the ... [more ▼]

BACKGROUND & AIMS: It is important to determine whether infliximab therapy can be safely interrupted in patients with Crohn's disease who have undergone a period of prolonged remission. We assessed the risk of relapse after infliximab therapy was discontinued in patients on combined maintenance therapy with antimetabolites and identified factors associated with relapse. METHODS: We performed a prospective study of 115 patients with Crohn's disease who were treated for at least 1 year with scheduled infliximab and an antimetabolite and had been in corticosteroid-free remission for at least 6 months. Infliximab was stopped, and patients were followed up for at least 1 year. We associated demographic, clinical, and biologic factors with time to relapse using a Cox model. RESULTS: After a median follow-up period of 28 months, 52 of the 115 patients experienced a relapse; the 1-year relapse rate was 43.9% +/- 5.0%. Based on multivariable analysis, risk factors for relapse included male sex, the absence of surgical resection, leukocyte counts >6.0 x 10(9)/L, and levels of hemoglobin </=145 g/L, C-reactive protein >/=5.0 mg/L, and fecal calprotectin >/=300 mug/g. Patients with no more than 2 of these risk factors (approximately 29% of the study population) had a 15% risk of relapse within 1 year. Re-treatment with infliximab was effective and well tolerated in 88% of patients who experienced a relapse. CONCLUSIONS: Approximately 50% of patients with Crohn's disease who were treated for at least 1 year with infliximab and an antimetabolite agent experienced a relapse within 1 year after discontinuation of infliximab. However, patients with a low risk of relapse can be identified using a combination of clinical and biologic markers. [less ▲]

Detailed reference viewed: 22 (3 ULg)
Full Text
Peer Reviewed
See detailProfile of Belgian Pediatric Crohn's Disease Patients: Associations between variables at diagnosis
De Greef, E; Hoffman, I; Smets, F et al

in Gastroenterology (2011), 140(5), 787

Detailed reference viewed: 13 (2 ULg)
Full Text
Peer Reviewed
See detailThe protease genes CYLD and USP40 are associated with Crohn's disease: results from a European Consortium
Cleynen, I; Artieda, M; Szczyoiorska, M et al

in Gastroenterology (2011), 140(5), 269

Detailed reference viewed: 13 (2 ULg)
Full Text
Peer Reviewed
See detailProfile of Belgian Pediatric Crohn's Disease Patients: Presentation and diagnostic features
De Greef, E; Hoffman, I; Smets, F et al

in Gastroenterology (2011), 140(5), 786

Detailed reference viewed: 14 (1 ULg)
Full Text
Peer Reviewed
See detailNetrin-1 Mediates Early Events in Pancreatic Adenocarcinoma Progression, Acting on Tumor and Endothelial Cells.
Dumartin, L.; Quemener, C.; Laklai, H. et al

in Gastroenterology (2010), 138(4), 1595-606

BACKGROUND & AIMS: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers. It is characterized by substantial tumor cell invasion and early-stage metastasis. We developed an in vivo ... [more ▼]

BACKGROUND & AIMS: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers. It is characterized by substantial tumor cell invasion and early-stage metastasis. We developed an in vivo model to analyze interactions between cancer and stromal cells during early stages of PDAC. METHODS: Human pancreatic adenocarcinoma cells were grafted onto the chick chorioallantoic membrane (CAM). Human and chicken GeneChips were used simultaneously to study gene regulation during PDAC cell invasion. Bioinformatic analysis was used to identify human orthologs and cell specificity of gene expression. The effects of netrin-1 encoded by NTN1 were investigated in adhesion, invasion, and apoptosis assays. The effects of NTN1 silencing with small interfering RNAs were investigated in PDAC cells in vivo. NTN1 expression was measured in human PDAC samples. RESULTS: PDAC cells rapidly invade the CAM stroma and remodel the CAM vasculature. More than 870 stromal genes were up-regulated by >2-fold; the angiogenesis regulators vascular endothelial growth factor D, thrombospondin 1, and CD151 were among the most highly regulated genes. Silencing of tumor cell NTN1, which is up-regulated 4-fold in the PDAC model, inhibited tumor cell invasion in vivo. Netrin-1 conferred apoptosis resistance to tumor and endothelial cells in vitro, induced their invasion, and provided an adhesive substrate for tumor cells. NTN1 and its gene product are strongly overexpressed in human PDAC samples. CONCLUSIONS: We developed a useful tool to study the invasive mechanisms of early-stage PDAC. Netrin-1 might be an important regulator of pancreatic tumor growth that functions in tumor and endothelial cells. [less ▲]

Detailed reference viewed: 53 (7 ULg)
Full Text
Peer Reviewed
See detailMolecular Reclassification of Crohn’s Disease by cluster analysis of genetic variants.
Cleynen, I.; Mahachie John, Jestinah ULg; Henckaerts, L. et al

in Gastroenterology (2010)

Detailed reference viewed: 17 (8 ULg)
Full Text
Peer Reviewed
See detailIntestinal mucosal expression of matrix metalloproteinase and ADAM genes in patients with inflammatory bowel disease and the impact of infliximab therapy
Arijs, Ingrid; Quintens, R.; Lemaire, K. et al

in Gastroenterology (2010), 138(5), 677

Detailed reference viewed: 11 (6 ULg)
Full Text
Peer Reviewed
See detailKinetics of C-Reactive Protein (CRP) following maintenance infliximab treatment in Crohn's disease identifies profiles of patients with better outcome
Jürgens, M.; Mahachie John, Jestinah ULg; Cleynen, I. et al

in Gastroenterology (2010), 138(5 (Suppl I)), -686

Detailed reference viewed: 16 (8 ULg)
Full Text
Peer Reviewed
See detailFibrin glue is effective healing perianal fistulas in patients with Crohn's disease.
Grimaud, Jean-Charles; Munoz-Bongrand, Nicolas; Siproudhis, Laurent et al

in Gastroenterology (2010), 138(7), 2275-8122811

BACKGROUND & AIMS: Fibrin glue is a therapeutic for fistulas that activates thrombin to form a fibrin clot, which mechanically seals the fistula tract. We assessed the efficacy and safety of a ... [more ▼]

BACKGROUND & AIMS: Fibrin glue is a therapeutic for fistulas that activates thrombin to form a fibrin clot, which mechanically seals the fistula tract. We assessed the efficacy and safety of a heterologous fibrin glue that was injected into the fistula tracts of patients with Crohn's disease (ClinicalTrials.gov No. NCT00723047). METHODS: This multicenter, open-label, randomized controlled trial included patients with a Crohn's disease activity index < or =250 and fistulas between the anus (or low rectum) and perineum, vulva, or vagina, that drained for more than 2 months. Magnetic resonance imaging or endosonography was performed to assess fistula tracts and the absence of abscesses. Patients were stratified into groups with simple or complex fistulas and randomly assigned to receive fibrin glue injections (n = 36) or only observation (n = 41) after removal of setons. The primary end point was clinical remission at week 8, defined as the absence of draining, perianal pain, or abscesses. At week 8, a fibrin glue injection was offered to patients who were not in remission. RESULTS: Clinical remission was observed in 13 of the 34 patients (38%) of the fibrin glue group compared with 6 of the 37 (16%) in the observation group; these findings demonstrate the benefit of fibrin glue (odds ratio, 3.2; 95% confidence interval: 1.1-9.8; P = .04). The benefit seemed to be greater in patients with simple fistulas. Four patients in the fibrin glue group and 6 in the observation group had adverse events. CONCLUSIONS: Fibrin glue injection is a simple, effective, and well-tolerated therapeutic option for patients with Crohn's disease and perianal fistula tracts. [less ▲]

Detailed reference viewed: 16 (0 ULg)
Full Text
Peer Reviewed
See detailThe impact of infliximab therapy on intestinal mucosal gene expression of endothelial cell adhesion molecules in patients with inflammatory bowel disease
Arijs, I.; Quintens, R.; Lemaire, K. et al

in Gastroenterology (2010), 138(5 Suppl I), -677

Detailed reference viewed: 9 (3 ULg)
Full Text
Peer Reviewed
See detailTECK and MADCAM-1 mucosal expression in active IBD: the effect of infliximab therapy
Arijs, I.; Van Lommel, L.; Van Steen, Kristel ULg et al

in Gastroenterology (2009), 136

Detailed reference viewed: 22 (2 ULg)
Full Text
Peer Reviewed
See detailThe impact of infliximab therapy on colonic mucosal expression of barrier genes in patients with inflammatory bowel disease
Arijs, I.; Quintens, R.; Van Lommel, L. et al

in Gastroenterology (2009), 136

Detailed reference viewed: 14 (5 ULg)
Full Text
Peer Reviewed
See detailPredictive Value of C-Reactive Protein Level Changes On the Long Term Outcome of Infliximab in Crohn's Disease
Jürgens, M.; Schnitzler, F.; Van Steen, Kristel ULg et al

in Gastroenterology (2009), 136(5), 171

Detailed reference viewed: 12 (5 ULg)
Full Text
Peer Reviewed
See detailMucosal gene signatures to predict response to infliximab in patients with inflammatory bowel disease.
Arijs, I.; Van Lommel, L.; Van Steen, Kristel ULg et al

in Gastroenterology (2008), 134

Detailed reference viewed: 16 (11 ULg)
Full Text
Peer Reviewed
See detailGenetic markers and the risk of complicated disease behaviour in Crohn's disease patients
Henckaerts, L.; Cleynen, I.; Joossens, M. et al

in Gastroenterology (2008), 134(4), 349-349

Detailed reference viewed: 16 (4 ULg)
Full Text
Peer Reviewed
See detailStability of gut microbiota over time in Crohn's disease patients compared to healthy relatives
Joossens, M.; De Preter, V.; Van Steen, Kristel ULg et al

in Gastroenterology (2008), 134(4), 653-653

Detailed reference viewed: 17 (8 ULg)